Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 13C Pyruvate MRI in Glioma
NCT03739411Phase 1Recruiting
- Start
- Dec 2015
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [1-13C]pyruvate in glioma (2 cohorts). Primary endpoints: Incidence of adverse events at 24 months, Peak lactate/pyruvate ratio in brain tissue at 24 months and 1 more. Started Dec 2015; status: recruiting.
02
Drugs
[1-13C]pyruvate
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03739411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739411.